keyword
MENU ▼
Read by QxMD icon Read
search

Hfpef

keyword
https://www.readbyqxmd.com/read/28730869/impact-of-iron-deficiency-on-exercise-capacity-and-outcome-in-heart-failure-with-reduced-mid-range-and-preserved-ejection-fraction
#1
Pieter Martens, Petra Nijst, Frederik H Verbrugge, Kevin Smeets, Matthias Dupont, Wilfried Mullens
BACKGROUND: Little information is available about the prevalence and impact on exercise capacity and outcome of iron deficiency in heart failure with mid-range (HFmrEF) and preserved (HFpEF) ejection fraction in comparison to heart failure with reduced ejection-fraction (HFrEF). Furthermore, no data is available about the progression of ID in patients without baseline anaemia. METHODS: We evaluated baseline iron and haemoglobin-status in a single-centre, prospective heart failure database...
July 21, 2017: Acta Cardiologica
https://www.readbyqxmd.com/read/28725953/prognostic-significance-of-low-systolic-blood-pressure-at-discharge-in-patients-with-heart-failure-and-preserved-ejection-fraction
#2
Shijun Li, Xiaoying Li
INTRODUCTION: Systolic blood pressure (SBP) is emerging as a predictor of outcome in chronic heart failure and low SBP has been shown to be related to higher mortality. AIM: To investigate the relationship between low SBP and long-term outcome in patients with heart failure with preserved ejection fraction (HFpEF). METHODS: We use prospectively collected data and recruited 297 patients with chronic HFpEF to investigate the relationship between low SBP at discharge and long-term outcome...
July 19, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/28716687/measures-of-ventricular-arterial-coupling-and-incident-heart-failure-preserved-ejection-fraction-hfpef-a-matched-case-control-analysis
#3
Carolyn L Lekavich, Debra J Barksdale, Jia-Rong Wu, Virginia Neelon, Jamie Crandell, Eric J Velazquez
OBJECTIVES: This study was designed to detect differences in markers associated with incident heart failure preserved ejection fraction (HFpEF) when comparing matched case-control groups. BACKGROUND: Evidence continues to demonstrate increasing prevalence, cost and mortality implications of HFpEF, but clearly defined parameters that distinguish between controls and HFpEF have not been established. METHODS: A study cohort of case (incident patients with HFpEF, n=155) and matched control (patients with no prior HF, n=155) groups was retrospectively identified...
July 14, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28714796/effect-of-bariatric-surgery-on-heart-failure
#4
Marcela Rodriguez Flores, Carlos Aguilar Salinas, Marie-Eve Piché, Audrey Auclair, Paul Poirier
Obesity increases the risk of heart failure (HF), which continues to be a significant proportion of all cardiovascular diseases and affects increasingly younger populations. The cross-talk between adipose and the heart involves insulin resistance, adipokine signaling and inflammation, with the capacity of adipose tissue to mediate hemodynamic signals, promoting progressive cardiomyopathy. Areas covered: From a therapeutic perspective, there is not yet a single obesity-related pathway that when addressed, can ameliorate cardiomyopathy in obese patients and this is a matter of ongoing research...
July 17, 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/28712998/brain-natriuretic-peptide-mediates-the-prognostic-role-of-renal-function-towards-10-year-cardiovascular-mortality-in-patients-with-acute-coronary-syndrome-the-hhf-study-2006-2016
#5
Christina Chrysohoou, George Georgiopoulos, Hara Kosyfa, Ioanna Kotsopoulou Haritou, Matina Kouvari, Androniki Filippou, Stelios Iosifidis, Eleftherios Tsiamis, Panagiotis Aggelopoulos, Christos Pitsavos, Dimitris Tousoulis
BACKGROUND/INTRODUCTION: Risk stratification in chronic heart failure (HF) remains a challenge. Renal function and B-natriuretic peptide (BNP) might confer predictive value towards long-term mortality in HF patients after an acute coronary syndrome (ACS). METHODS: From May 2006 to March 2009, 1,000 consecutive patients who were hospitalized with ACS diagnosis were enrolled in the study. In 2016, the 10-year follow-up (2006-2016) was performed in 745 participants...
July 13, 2017: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/28711451/atrial-fibrillation-in-heart-failure-with-preserved-mid-range-and-reduced-ejection-fraction
#6
Ulrik Sartipy, Ulf Dahlström, Michael Fu, Lars H Lund
OBJECTIVES: The study sought to assess the independent risk factors for, consequences of, and outcomes with atrial fibrillation (AF) compared with sinus rhythm (SR) in heart failure (HF) with preserved ejection fraction (HFpEF) versus HF with mid-range ejection fraction (HFmrEF) versus HF with reduced ejection fraction (HFrEF). BACKGROUND: AF is common in HF, but most data are from HFrEF. The importance of AF in HFpEF and MFmrEF is less well known. METHODS: In patients from 2000 to 2012 in the SwedeHF (Swedish Heart Failure Registry) registry, enriched with patient-level data from national health care registries, the authors assessed prevalence of, associations with and prognostic impact of AF in HFpEF versus HFmrEF versus HFrEF...
July 6, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28711449/intrarenal-flow-alterations-during-transition-from-euvolemia-to-intravascular-volume-expansion-in-heart-failure-patients
#7
Petra Nijst, Pieter Martens, Matthias Dupont, W H Wilson Tang, Wilfried Mullens
OBJECTIVES: The goal of this study was to assess: 1) the intrarenal flow in heart failure (HF) patients during the transition from euvolemia to intravascular volume overload; and 2) the relationship between intrarenal flow and diuretic efficiency. BACKGROUND: Intrarenal blood flow alterations may help to better understand impaired volume handling in HF. METHODS: Resistance index (RI) and venous impedance index (VII) were assessed in 6 healthy subjects, 40 euvolemic HF patients with reduced ejection fraction (HFrEF) and 10 HF patients with preserved ejection fraction (HFpEF)...
July 6, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28706575/targeting-endothelial-function-to-treat-heart-failure-with-preserved-ejection-fraction-the-promise-of-exercise-training
#8
REVIEW
Andreas B Gevaert, Katrien Lemmens, Christiaan J Vrints, Emeline M Van Craenenbroeck
Although the burden of heart failure with preserved ejection fraction (HFpEF) is increasing, there is no therapy available that improves prognosis. Clinical trials using beta blockers and angiotensin converting enzyme inhibitors, cardiac-targeting drugs that reduce mortality in heart failure with reduced ejection fraction (HFrEF), have had disappointing results in HFpEF patients. A new "whole-systems" approach has been proposed for designing future HFpEF therapies, moving focus from the cardiomyocyte to the endothelium...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28705910/fatigability-exercise-intolerance-and-abnormal-skeletal-muscle-energetics-in-heart-failure
#9
Kilian Weiss, Michael Schär, Gurusher S Panjrath, Yi Zhang, Kavita Sharma, Paul A Bottomley, Asieh Golozar, Angela Steinberg, Gary Gerstenblith, Stuart D Russell, Robert G Weiss
BACKGROUND: Among central and peripheral factors contributing to exercise intolerance (EI) in heart failure (HF), the extent to which skeletal muscle (SM) energy metabolic abnormalities occur and contribute to EI and increased fatigability in HF patients with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively) are not known. An energetic plantar flexion exercise fatigability test and magnetic resonance spectroscopy were used to probe the mechanistic in vivo relationships among SM high-energy phosphate concentrations, mitochondrial function, and EI in HFrEF and HFpEF patients and in healthy controls...
July 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28702858/effect-of-renin-angiotensin-system-inhibitors-on-mortality-in-heart-failure-with-preserved-ejection-fraction-a-meta-analysis-of-observational-cohort-and-randomized-controlled-studies
#10
REVIEW
Hidekatsu Fukuta, Toshihiko Goto, Kazuaki Wakami, Nobuyuki Ohte
Despite the high mortality rate, there is no therapy to improve survival in heart failure with preserved ejection fraction (HFpEF). Large randomized controlled trials (RCTs) did not show clear mortality benefit of renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) in HFpEF. However, because of the strict enrollment criteria, the patients who participated in these trials might represent a selected group of patients that is poorly representative of patients treated in routine clinical practice...
July 12, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28693409/long-term-outcomes-in-patients-with-critical-limb-ischemia-and-heart-failure-with-preserved-or-reduced-ejection-fraction
#11
Kavita B Khaira, Ellen Brinza, Gagan D Singh, Ezra A Amsterdam, Stephen W Waldo, Kathleen Tong, Kruti Pandya, John R Laird, Ehrin J Armstrong
The impact of heart failure (HF) on long-term survival in patients with critical limb ischemia (CLI) has not been well described. Outcomes stratified by left ventricular ejection fraction (EF) are also unknown. A single center retrospective chart review was performed for patients who underwent treatment for CLI from 2006 to 2013. Baseline demographics, procedural data and outcomes were analyzed. HF diagnosis was based on appropriate signs and symptoms as well as results of non-invasive testing. Among 381 CLI patients, 120 (31%) had a history of HF and 261 (69%) had no history of heart failure (no-HF)...
July 1, 2017: Vascular Medicine
https://www.readbyqxmd.com/read/28684221/exercise-training-for-prevention-and-treatment-of-heart-failure
#12
REVIEW
Nitin Kondamudi, Mark Haykowsky, Daniel E Forman, Jarett Berry, Ambarish Pandey
Heart Failure (HF) results in high healthcare costs and burdens for the United States both in respects to hospitalizations, therapies, and associated disability. The relative proportion of HF with preserved ejection fraction (HFpEF) compared with HF with reduced ejection fraction (HFrEF) is on the rise; HFpEF has already become the dominant form of HF and it continues to increase. The serious implications of these trends are compounded by a dearth of effective HFpEF therapies. While low physical activity, low cardiorespiratory fitness (CRF), and obesity, are risk factors for HF in general, they particularly predispose to HFpEF...
July 3, 2017: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/28683960/arterial-stiffening-with-exercise-in-patients%C3%A2-with-heart-failure-and-preserved%C3%A2-ejection-fraction
#13
Yogesh N V Reddy, Mads J Andersen, Masaru Obokata, Katlyn E Koepp, Garvan C Kane, Vojtech Melenovsky, Thomas P Olson, Barry A Borlaug
BACKGROUND: Aortic stiffening and reduced nitric oxide (NO) availability may contribute to the pathophysiology of heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: This study compared indices of arterial stiffness at rest and during exercise in subjects with HFpEF and hypertensive control subjects to examine their relationships to cardiac hemodynamics and determine whether exertional arterial stiffening can be mitigated by inorganic nitrite. METHODS: A total of 22 hypertensive control subjects and 98 HFpEF subjects underwent hemodynamic exercise testing with simultaneous expired gas analysis to measure oxygen consumption...
July 11, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28681133/innovative-clinical-trial-designs-for-precision-medicine-in-heart-failure-with-preserved-ejection-fraction
#14
Sanjiv J Shah
A major challenge in the care of patients with heart failure and preserved ejection fraction (HFpEF) is the lack of proven therapies due to disappointing results from randomized controlled trials (RCTs). The heterogeneity of the HFpEF syndrome and the use of conventional RCT designs are possible reasons underlying the failure of these trials. There are several factors-including the widespread adoption of electronic health records, decreasing costs of obtaining high-dimensional data, and the availability of a wide variety of potential therapeutics-that have evolved to enable more innovative clinical trial designs in HFpEF...
June 2017: Journal of Cardiovascular Translational Research
https://www.readbyqxmd.com/read/28678923/cardiac-amyloidosis-and-its-new-clinical-phenotype-heart-failure-with-preserved-ejection-fraction
#15
Evandro Tinoco Mesquita, Antonio José Lagoeiro Jorge, Celso Vale Souza, Thais Ribeiro de Andrade
Heart failure with preserved ejection fraction (HFpEF) is now an emerging cardiovascular epidemic, being identified as the main phenotype observed in clinical practice. It is more associated with female gender, advanced age and comorbidities such as hypertension, diabetes, obesity and chronic kidney disease. Amyloidosis is a clinical disorder characterized by the deposition of aggregates of insoluble fibrils originating from proteins that exhibit anomalous folding. Recently, pictures of senile amyloidosis have been described in patients with HFpEF, demonstrating the need for clinical cardiologists to investigate this etiology in suspect cases...
June 29, 2017: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/28676030/heart-failure-with-preserved-ejection-fraction-a-dilemma-in-treatment-options
#16
Taylor Bramblett, Mohamed Teleb, Aymen Albaghdadi, Harsh Agrawal, Debabrata Mukherjee
Heart failure with preserved ejection fraction (HFpEF) makes up half of diagnosed heart failure cases and has similar outcomes compared to heart failure with reduced ejection fraction (HFrEF) but a discrepancy in knowledge and approach to treatment. HFpEF is diagnosed using the following criteria: symptoms, preserved ejection fraction (greater than 50%), and evidence of abnormal left ventricular filling or relaxation, or diastolic distensibility or stiffness. Studies conducted to examine the efficacy of angiotensin receptor blockers (irbesartan and candesartan), thiazide diuretics (chlorthalidone), and angiotensin converting enzyme inhibitors (perindopril) in the treatment of HFpEF, showed moderate efficacy but no clear benefit...
July 3, 2017: Cardiovascular & Hematological Disorders Drug Targets
https://www.readbyqxmd.com/read/28674618/higher-number-of-live-births-is-associated-with-left-ventricular-diastolic-dysfunction-and-adverse-cardiac-remodelling-among-us-hispanic-latina-women-results-from-the-echocardiographic-study-of-latinos
#17
Shivani R Aggarwal, David M Herrington, Catherine J Vladutiu, Jill C Newman, Katrina Swett, Franklyn Gonzalez, Jorge R Kizer, Michelle A Kominiarek, Karen M Tabb, Linda C Gallo, Gregory A Talavera, Barry E Hurwitz, Carlos J Rodriguez
INTRODUCTION: Female sex is a risk factor for heart failure with preserved ejection fraction (HFpEF). Previous literature suggests that some diastolic dysfunction (DD) develops during pregnancy and may persist postdelivery. Our objective was to examine the relationship between parity and cardiac structure and function in a population-based cohort. METHODS: Participants included 1172 Hispanic/Latina women, aged ≥45 years, enrolled in the Echocardiographic Study of Latinos from four US communities (Bronx, Miami, San Diego and Chicago)...
2017: Open Heart
https://www.readbyqxmd.com/read/28673328/effect-of-a-6-month-pedometer-based-walking-intervention-on-functional-capacity-in-patients-with-chronic-heart-failure-with-reduced-hfref-and-with-preserved-hfpef-ejection-fraction-study-protocol-for-two-multicenter-randomized-controlled-trials
#18
Tomas Vetrovsky, Michal Siranec, Jiri Parenica, Martin Griva, Jiri Stastny, Jan Precek, Radek Pelouch, Vaclav Bunc, Ales Linhart, Jan Belohlavek
BACKGROUND: Regular physical activity is recommended for patients with chronic heart failure to improve their functional capacity, and walking is a popular, effective, and safe form of physical activity. Pedometers have shown potential to increase the amount of walking across a range of chronic diseases, but it is unknown whether a pedometer-based intervention improves functional capacity and neurohumoral modulation in heart failure patients. METHODS: Two multicenter randomized controlled trials will be conducted in parallel: one in patients with chronic heart failure with reduced ejection fraction (HFrEF), the other in patients with chronic heart failure with preserved ejection fraction (HFpEF)...
July 3, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28666951/peak-exercise-oxygen-uptake-predicts-recurrent-admissions-in-heart-failure-with-preserved-ejection-fraction
#19
Patricia Palau, Eloy Domínguez, Eduardo Núñez, José María Ramón, Laura López, Joana Melero, Juan Sanchis, Alejandro Bellver, Enrique Santas, Antoni Bayes-Genis, Francisco J Chorro, Julio Núñez
INTRODUCTION AND OBJECTIVES: Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with an elevated risk of morbidity and mortality. To date, there is scarce evidence on the role of peak exercise oxygen uptake (peak VO2) for predicting the morbidity burden in HFpEF. We sought to evaluate the association between peak VO2 and the risk of recurrent hospitalizations in patients with HFpEF. METHODS: A total of 74 stable symptomatic patients with HFpEF underwent a cardiopulmonary exercise test between June 2012 and May 2016...
June 27, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28662936/angiotensin-receptor-neprilysin-inhibition%C3%A2-in-heart-failure-with-preserved%C3%A2-ejection-fraction-rationale-and-design-of-the-paragon-hf-trial
#20
REVIEW
Scott D Solomon, Adel R Rizkala, Jianjian Gong, Wenyan Wang, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske, Margaret M Redfield, Jean L Rouleau, Dirk J Van Veldhuisen, Faiez Zannad, Michael R Zile, Akshay S Desai, Victor C Shi, Martin P Lefkowitz, John J V McMurray
OBJECTIVES: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). BACKGROUND: HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes...
July 2017: JACC. Heart Failure
keyword
keyword
6587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"